Different effects of 7-nitroindazole in reserpine-induced hypolocomotion in two strains of mice

European Journal of Pharmacology

Volumn 535, Issue 1-3, 2006, Pages 199-207

  Tadaiesky, Meigy T ^a   Andreatini, Roberto ^a   Vital, Maria A B F ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

(Mice); 7 Nitroindazole; C57BL 6; Nitric oxide synthase; Reserpine; Swiss

Indexed keywords

7 NITROINDAZOLE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; RESERPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; LOCOMOTION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ENZYME INHIBITORS; INDAZOLES; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NITRIC OXIDE SYNTHASE; RESERPINE; SPECIES SPECIFICITY; TIME FACTORS;

EID: 33645412107     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.02.004     Document Type: Article

References (74)

1. V.C. Abílio, C.C.S. Araujo, M. Bergamo, P.R.V. Calvente, V.D. Almeida, R. de A. Ribeiro, and R. Frussa-Filho Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 2003 109 114
2. J.A. Aguirre, J. Kehr, T. Yoshitake, F. Liu, A. Rivera, S. Fernandez-Espinola, B. Andbjer, G. Leo, A.D. Medhurst, L.F. Agnati, and K. Fuxe Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP Brain Res. 1033 2005 216 220
3. S.F. Ali, and Y. Itzhak Effects of 7-nitroindazole, an NOS inhibitor on methamphetamine-induced dopaminergic and serotonergic neurotoxicity in mice Ann. N. Y. Acad. Sci. 844 1998 122 130
4. F. Antunes, C. Nunes, J. Laranjinha, and E. Cadenas Redox interactions of nitric oxide with dopamine and its derivatives Toxicology 208 2005 207 212
5. T. Araki, H. Mizutani, M. Matsubara, Y. Imai, M. Mizugaki, and Y. Itoyama Nitric oxide synthase inhibitors cause motor deficits in mice Eur. Neuropsychopharmacol. 11 2001 125 133
6. J.S. Bains, and C.A. Shaw Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death Brain Res. Rev. 25 1997 335 358
7. J.S. Beckman, J. Chen, J.P. Crow, and Y.Z. Ye Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration Prog. Brain Res. 103 1994 371 380
8. E. Berdichevsky, N. Riveros, S. Sánchez-Armáss, and F. Orrego Kainate, N-methylaspartate and other excitatory amino acids increase calcium influx into rat brain cortex cells in vitro Neurosci. Lett. 36 1983 75 80
9. M.D. Black, E.K. Matthews, and P.P. Humphrey The effects of a photosensitive nitric oxide donor on basal and electrically-stimulated dopamine efflux from the rat striatum in vitro Neuropharmacology 33 1994 1357 1365
10. + accumulation Neuropharmacology 39 2000 1016 1020
11. D.S. Bredt, and S.H. Snyder Nitric oxide mediates glutamate linked enhancement of cGMP levels in the cerebellum Proc. Natl. Acad. Sci. U. S. A. 87 1989 9030 9033
12. O. Bugnon, N.C. Schaad, and M. Schorderet Nitric oxide modulates endogenous dopamine release in bovine retina Neuroreport 5 1994 401 404
13. K. Castagnoli, S. Palmer, A. Anderson, T. Bueters, and N. Castagnoli Jr. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-b-catalyzed oxidation of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine Chem. Res. Toxicol. 10 1997 364 368
14. D. Centonze, P. Gubellini, S. Rossi, B. Picconi, A. Pisani, G. Bernardi, P. Calabresi, and C. Baunez Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism Neuroscience 133 2005 831 840
15. A. Cheramy, R. Romo, G. Godeheu, P. Baruch, and J. Glowinski In vivo presynaptic control of dopamine release in the cat caudate nucleus: II. Facilitatory or inhibitory role of l-glutamate Neuroscience 19 1986 1081 1090
16. D.W. Clow, and K. Jhamandias Characterisation of l-glutamate action on the release of endogenous dopamine from the rat caudate-putamen J. Pharmacol. Exp. Ther. 248 1989 722 727
17. F.C. Colpaert Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rats Neuropharmacology 26 1987 1431 1440
18. T.M. Dawson, and V.L. Dawson Molecular pathways of neurodegeneration in Parkinson's disease Science 302 2003 819 822
19. V.L. Dawson, T.M. Dawson, D.A. Bartley, G.R. Uhl, and S.H. Snyder Mechanism of nitric oxide-mediated neurotoxicity in primary brain cultures J. Neurosci. 13 1993 2651 2661
20. D.A. Di Monte, J.E. Royland, A. Anderson, K. Castagnoli, N. Castagnoli Jr., and J.W. Langston Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity J. Neurochem. 69 1997 1771 1773
21. D.J. Eve, A.P. Nisbet, A.E. Kingsbury, E.L. Hewson, S.E. Daniel, A.J. Lees, C.D. Marsden, and O.J. Foster Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease Brain Res. Mol. Brain Res. 63 1998 62 71
22. J. Garthwaite, S.L. Charles, and R. Chess-Williams Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain Nature 336 6197 1988 385 388
23. J. Garthwaite, G. Garthwaite, R.M. Palmer, and S. Moncada NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices Eur. J. Pharmacol. 172 1989 413 416
24. A. Giovanni, B.A. Sieber, R.E. Heikkila, and P.K. Sonsalla Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration to several strains of mice Am. Soc. Pharmacol. Exp. Ther. 257 1991 691 697
25. P. Goodwin, B.S. Starr, and B.S. Starr Motor responses to dopamine D1 and D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK 801 J. Neural Transm. 4 1992 15
26. R. Guevara-Guzman, P.C. Emson, and K.M. Kendrick Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP Neurochemistry 62 1994 807 810
27. P. Hantraye, E. Brouillet, R. Ferrante, S. Palfi, R. Dolan, R.T. Matthews, and M.F. Beal Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons Nat. Med. 2 1996 1017 1021
28. R. Haobam, K.M. Sindhu, G. Chandra, and K.P. Mohanakumar Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains Behav. Brain Res. 163 2 2005 159 167
29. K.E. Heikkila, L. Manzino, F.S. Cabbat, and R.C. Duvoisin Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine by monoamine oxidase inhibitors Nature 311 1984 467 469
30. O. Hornykiewicz Dopamine (3-hydroxytyramine) and brain function Pharmacol. Rev. 18 1966 925 964
31. M.M. Iravani, J. Millar, and Z.L. Kruk Differential release of dopamine by nitric oxide in subregions of rat caudate putamen slices J. Neurochem. 71 1998 1969 1977
32. P. Jenner, and C.W. Olanow Oxidative stress and the pathogenesis of Parkinson's disease Neurology 47 1996 161 170
33. S. Kaur, and M.S. Starr Antiparkinsonian action of dextramethorphan in the reserpine-treated mouse Eur. J. Pharmacol. 280 1995 159 166
34. J.P. Kiss, E.C. Hennings, G. Zsilla, and E.S. Vizi A possible role of nitric oxide in the regulation of dopamine transporter function in the striatum Neurochem. Int. 34 1999 345 350
35. P. Klivenyi, O.A. Andreassen, R.J. Ferrante, E. Lancelot, D. Reif, and M.F. Beal Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity Neuroreport 11 2000 1265 1268
36. R.G. Knowles, and S. Moncada Nitric oxide synthase in mammals Biochem. J. 298 1994 49 258
37. S.K. Lai, T.K.Y. Ng, W.K. Lau, M.S. Yang, C.K.C. Wong, Y.S. Chan, and K.K.L. Yung Selective knockdown of gene expression of N-methyl-d-aspartate receptor one ameliorates parkinsonian motor symptom in 6-hydroxydopamine- lesioned rats Neurochem. Int. 45 2004 11 22
38. V. Leviel, A. Gobert, and B. Guibert The glutamate-mediated release of dopamine: further characterisation of the dual excitatory-inhibitory function Neuroscience 39 1990 305 312
39. L.P. Liang, and S. Kaufman The regulation of dopamine release from striatum slices by tetrahydrobiopterin and l-arginine-derived nitric oxide Brain Res. 800 1998 181 186
40. N. Lindefors, and U. Ungerstedt Bilateral regulation of glutamate tissue antagonists increase the release of dopamine in the substantia of extracellular levels in caudate-putamen by midbrain dopamine neurones Neurosci. Lett. 115 1990 248 252
41. T. McCall, and P. Vallance Nitric oxide takes centre-stage with newly defined roles Trends Pharmacol. Sci. 13 1992 1
42. F. Menzaghi, K.T. Whelan, V.B. Risbrough, T.S. Rao, and G.K. Lloyd Interactions between a novel cholinergic ion chanela agonist, SIB-1765F and l-DOPA in the reserpine model of Parkinson's disease in rats J. Pharmacol. Exp. Ther. 280 1997 393 401
43. N. Mitra, K.P. Mohanakumar, and D.K. Ganguly Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrehydropyridine: relationship with low levels of regional monoamine oxidase-B J. Neurochem. 62 1994 1906 1912
44. P.K. Moore, P. Wallace, Z. Gaffen, S.L. Hart, and R.C. Babbedge Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: antinociceptive and cardiovascular effects Br. J. Pharmacol. 110 1993 219
45. M. Morelli, S. Fenu, A. Pinna, and G. Di Chiara Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behaviour in the 6-hydroxydopamine model of turning: relationship with c-fos expression J. Pharmacol. Exp. Ther. 260 1992 402
46. U. Muthane, K.A. Ramsay, H. Jiang, V. Jackson-Lewis, D. Donaldson, S. Fernaldo, M. Ferreira, and S. Prezdborski Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 and CD-1mice Exp. Neurol. 126 1994 195 204
47. T.L. Perry, D.V. Godin, and S. Hansen Parkinson's disease: a disorder due to nigral glutathione deficiency Neurosci. Lett. 33 1982 305 310
48. S. Przedborski, V. Jackson-Lewis, and R. Yokoyama Nitric oxide-mediated toxicity in an animal model of Parkinson's disease Neurology 46 1996 408
49. D. Pubill, C. Chipana, A. Camins, M. Pallàs, J. Camarasa, and E. Escubedo Free radical production induced by methamphetamine in rat striatal synaptosomes Toxicol. Appl. Pharmacol. 204 2005 57 68
50. P. Riederer, E. Sofie, W.D. Rausch, B. Schmidt, G.P. Reynolds, K. Jellinger, and M.B.H. Youdim Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains J. Neurochem. 52 1989 515 520
51. M. Sedelis, K. Hofele, G.W. Auburger, and J.P. Huston MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analyses of gender and strain differences Behav. Genet. 30 2000 171 182
52. A. Seilicovich, M. Lasaga, M. Befumo, B.H. Duvilanski, M. Del Carmen Diaz, V. Rettori, and S.M. McCann Nitric oxide inhibits the release of norepinephrine and dopamine from the medial basal hypothalamus of the rat Proc. Natl. Acad. Sci. U. S. A. 92 1995 11299 11302
53. J. Sian, D.T. Dexter, A.J. Lees, S.E. Daniel, Y. Agid, F. Javoy-Agid, P. Jenner, and C.D. Marsden Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Ann. Neurol. 36 1994 348 355
54. M.T. Silva, S. Rose, J.G. Hindmarsch, G. Aislaitner, J.W. Gorrod, P.K. Moore, P. Jenner, and C.D. Marsden Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitroindazole Br. J. Pharmacol. 114 1995 257 258
55. T.P. Singer, N. Castagnoli, R.R. Ramsay, and A.J. Trevor Biochemical events in the development of parkinsonism induced by 1-methyl, 4-phenyl, 1,2,3,6-tetrahydropyridine J. Neurochem. 49 1987 1 8
56. L.L. Skalisz, V. Beijamini, S.L. Joca, M.A.B.F. Vital, C. Da Cunha, and R. Andreatini Evaluation of the face validity of reserpine administration as an animal model of depression-Parkinson's disease association Prog. Neuro-Psychopharmacol. Biol. Psychiatry 26 2002 879 883
57. M. Smeyne, O. Goloubeva, and R.J. Smeyne Strain-dependent susceptibility to MPTP and MPTP (+)-induced parkinsonism is determined by glia Glia 34 2001 73 80
58. S.H. Snyder, and D.S. Bredt Nitric oxide as a neuronal messenger Trends Pharmacol. Sci. 12 1991 125
59. S.H. Snyder, and D.S. Bredt Biological roles of nitric oxide Sci. Am. 266 1992 18 35
60. 2 balance in the basal ganglia modulation and Parkinson's disease, and its relevance to Parkinson's disease Synapse 19 1995 264 293
61. M.S. Starr, and B.S. Starr Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine receptor agonists in reserpine-treated mice Psychopharmacology 114 1994 469 476
62. M.S. Starr, and B.S. Starr Do NMDA receptor-mediated changes in motor behaviour involve nitric oxide? Eur. J. Pharmacol. 272 1995 211 217
63. A. Strasser, R.M. McCarron, H. Ishii, D. Stanimirovic, and M. Spatz l-Arginine induces dopamine release from the striatum in vivo Neuroreport 5 1995 2298 2300
64. E. Sundstrom, I. Stromberg, T. Tsutsumi, L. Olson, and G. Jonsson Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice Brain Res. 405 1987 26 38
65. M. Toborek, and B. Henning Fatty acid-mediated effects on the glutathione redox cycle in cultured endothelial cells Am. J. Clin. Nutr. 59 1994 60 65
66. S. Toffa, G.M. Kunikowska, P. Jenner, and C.D. Marsden Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration J. Neural Transm. 104 1997 67 75
67. J.L. Vincent, and B.T. Hope Neurons that say NO Trends Neurosci. 15 1992 108
68. G.F. Weber Final common pathways in neurodegenerative diseases: regulatory role of the glutathione cycle Neurosci. Biobehav. Rev. 23 1999 1079 1086
69. A.R. West, and M.P. Galloway Nitric oxide and potassium chloride-facilitated striatal dopamine efflux in vivo: role of calcium-dependent release mechanisms Neurochem. Int. 33 6 1998 493 501
70. A.R. West, M.P. Galloway, and A.A. Grace Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms Synapse 44 2002 227 245
71. M.B.H. Youdim, and P. Riederer Understanding Parkinson's disease Sci. Am. 276 1 1997 52 59
72. J. Zimmer, and F.A. Geneser Difference in monoamine oxidase B activity between C57 black and albino NMRI mouse strains may explain differential effects of the neurotoxin MPTP Neurosci. Lett. 78 1987 253 258
73. M.Y Zhu, and A.V. Juorio Aromatic l-amino-acid decarboxylase: biological characterization and functional role Gen. Pharmacol. 26 1995 681 696
74. X.Z. Zhu, and L.G. Luo Effect of nitroprusside (nitric oxide) on endogenous dopamine release from rat striatal slices J. Neurochem. 59 1992 932 935